0000950170-23-047519.txt : 20230911 0000950170-23-047519.hdr.sgml : 20230911 20230911170510 ACCESSION NUMBER: 0000950170-23-047519 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230908 FILED AS OF DATE: 20230911 DATE AS OF CHANGE: 20230911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brannan Stephen K. CENTRAL INDEX KEY: 0001777631 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38958 FILM NUMBER: 231248395 MAIL ADDRESS: STREET 1: C/O KARUNA THERAPEUTICS, INC. STREET 2: 33 ARCH STREET, SUITE 3110 CITY: BOSTON STATE: MA ZIP: 02110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karuna Therapeutics, Inc. CENTRAL INDEX KEY: 0001771917 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270605902 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-449-2244 MAIL ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 4 1 ownership.xml 4 X0508 4 2023-09-08 false 0001771917 Karuna Therapeutics, Inc. KRTX 0001777631 Brannan Stephen K. C/O KARUNA THERAPEUTICS, INC. 99 HIGH STREET, 26TH FLOOR BOSTON MA 02110 true Chief Medical Officer true Common Stock 2023-09-08 4 M false 2500 5.45 A 28650 D Common Stock 2023-09-08 4 M false 5000 131.64 A 33650 D Common Stock 2023-09-08 4 S false 1276 183.07 D 32374 D Common Stock 2023-09-08 4 S false 2756 184.13 D 29618 D Common Stock 2023-09-08 4 S false 908 185.03 D 28710 D Common Stock 2023-09-08 4 S false 60 185.60 D 28650 D Option (right to buy) 5.45 2023-09-08 4 M false 2500 0 D 2027-06-01 Common Stock 2500 19677 D Option (right to buy) 131.64 2023-09-08 4 M false 5000 0 D 2031-02-22 Common Stock 5000 41350 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.45 to $183.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.58 to $184.57, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $184.58 to $185.50, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.58 to $185.63, inclusive. This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter. This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of February 23, 2021, with additional vesting as to 6.25% of the shares underlying the option award at the end of each three month period thereafter. /s/ Troy Ignelzi, Attorney-in-Fact 2023-09-11